On January 29, 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. The IPO comprises a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). The implied market capitalization of the company, assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, is approximately CHF 212.9 m. The first day of trading is expected to be February 7, 2025.
BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The Company’s most advanced R&D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in in Lille, France, Delaware, United States and Guangzhou, China.
Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud & Cie SA and Octavian AG as Selling Agents.
Homburger is advising BioVersys on all aspects of the IPO as lead counsel. The Homburger team is co-led by Dieter Gericke and Lorenzo Togni and includes Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all Corporate / M&A and Capital Markets). Luca Dal Molin and Kristina Martinovic (both IP / IT) are providing intellectual property advice, Jeremy Reichlin (Employment and Executive Compensation) is providing employment and executive compensation advice, and Reto Heuberger and Philippe Weber (both Tax) are providing tax advice.